Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to AtherosclerosisReferences
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33.
- Heart and Estrogen/progestin Replacement Study (HERS). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.JAMA. 1998; 280: 605-612
- Effects of estrogen replacement on the progression of coronary artery atherosclerosis.N. Eng. J. Med. 2000; 343: 522-529
- Mechanisms of cardioprotection by estrogens.Proc. Soc. Expt. Biol. Med. 1998; 217: 23-29
F-D-C Reports. Wyeth–Ayerst commits to characterization of Premarin. FDA says. Generic conjugates may not be approved until Premarin is characterized. F-D-C Reports, Chevy Chase, MD, 1997, May 12, p. 3–5.
The Coronary drug Project. Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 1973;226:652–7.
- Estrogen in the prevention of atherosclerosis: a randomized double-blind, placebo controlled trial.Ann. Intern. Med. 2001; 135: 939-953